Applied DNA Sciences WKN: A2PUTA ISIN: US03815U3005 Forum: Aktien Thema: Hauptdiskussion

Irgendwie hört dieses Messer niemals auf zu fallen...

Warum geht nicht hoch diese **** Keine Boden gefunden 2 geht hoch 5 Cent runter

Das Ding kennt keinen Boden. Oder doch?

Kauf*

Meiner unprofessionellen Meinung nach mit EK 11.67 würd ich sagen lass es und laif was anderes :D

Kaufen oder nich?

Nicht mehr lange dann sind wir bei 0,00 🤝🏻 tschüss mit diesem Jauche Unternehmen

Same :D

eigentlich waren die Zahlen mMn top. Wie auch immer, ich verbuche den Wert als Depot-Witz ... werde hier halten, aber mich nicht mehr mit der Firma befassen. Allen alles Gute hier

Ein Kurs schön am AZT… habe gehofft bei meinem Kauf bei 2,89 € schön nah am Boden zu sein. Hat von Euch jemand nähere Informationen? So katastrophal waren die Zahl aus meiner Sicht doch nicht.

Earning Call war ja wohl ein Fall mit X

https://www.pressviewer.com/ViewEmail.asp?b=2592&id=222415&p=2217929&I=1285530-w8K3N4N9E6

STONY BROOK, N.Y. - Applied DNA Sciences, Inc. (NASDAQ: APDN) (the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, announced today that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs, LLC (ADCL), has submitted a request to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) for its Linea™ 2.0 COVID-19 Assay (the "Linea 2.0 Assay") and Linea™ Unsupervised At-Home Sample Collection Kit (the "Linea Collection Kit"). If approved, the Company's request for EUA positions ADCL to pursue an expansion of its established safeCircle™ COVID-19 testing platform nationally to meet the needs of enterprises seeking to protect workforce health and avoid disruptions to operations by mass staff absences due to Omicron's high transmissibility and ability to evade vaccination immunity. ADCL's safeCircle program is a fully integrated testing platform for enterprise and educational institutions that provides a full range of COVID-19 diagnostic testing and associated services, including sample collection, test site infrastructure design and management, results tracking, and vaccination status management. The Linea 2.0 Assay is a high-throughput multiplex RT-PCR assay targeting the E and N genes of SARS-CoV-2. The Assay is variant agnostic, can detect all known SARS-CoV-2 variants, and is validated for single sample and robotic pooled testing. The Assay previously received conditional approval from the New York State Department of Health in late December 2021. The Linea Collection Kit is designed to enable the simple self-collection of nasal swab specimens without supervision by medical personnel. Once collected, individual samples can be mailed directly back to ADCL or aggregated by a testing client and bulk shipped back to ADCL. Results are typically returned within 24-to-48 hours of a sample's arrival at ADCL's clinical lab. "The unprecedented surge in COVID-19 cases driven by the Omicron variant, we believe, makes clear that the need for accurate and rapid PCR-based testing is more important than ever. We believe this EUA request positions us to service existing demand for enterprise-scale COVID-19 testing with a compelling selling proposition where remote work is not a scalable option and a dependence on less sensitive, antigen-based tests can potentially lead to outbreaks and interruptions in business continuity. Having proved the safeCircle platform in New York State, we are pursuing partnerships and contract opportunities to establish safeCircle nationally," stated Dr. James A. Hayward, president and CEO of Applied DNA. "At the same time, while safeCircle was formed specifically to build a COVID-19 testing platform, the potential acquisition of a national customer base advances ADCL's strategy to expand its diagnostic offerings beyond SARS-CoV-2 with an installed client base."